NCT05883644 2026-02-18
SIERRA
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
3 trialsNCT03937830 2026-02-05
Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05301842 2025-01-15
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting